Immatics N.V.
IMTX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001809196
In the last 90 days, Immatics N.V. insiders filed 1 open-market purchase and 0 sales; 82 institutions reported holding it in 13F filings for Q2 2026, worth $1.01B in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding Immatics N.V. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 49 | 47 | −2 |
| Shares | 23.0M | 21.7M | −1.37M (−6.0%) |
| Value | $309.5M | $173.0M | −$136.5M (−44.1%) |
New holders (3)
Institutions that held Immatics N.V. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Millennium Management LLC | 37,427 | $299.0K | 0.00% |
| Lazard Asset Management LLC | 10,598 | $84.0K | 0.00% |
| BlackRock Inc. | 3,300 | $27.0K | 0.00% |
Sold out (5)
Institutions that held Immatics N.V. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Altium Capital Management LP | 469,980 | $6.32M |
| Gyon Technologies Capital Management, LP | 32,423 | $436.0K |
| Citadel Advisors LLC | 10,599 | $143.0K |
| Marshall Wace, LLP | 2,982 | $41.0K |
| Wolverine Asset Management LLC | 1,157 | $15.0K |